Consumer Health Digest #19-48

Your Weekly Update of News and Reviews
December 8, 2019

Consumer Health Digest is a free weekly e-mail newsletter edited by William M. London, Ed.D., M.P.H., with help from Stephen Barrett, M.D. It summarizes scientific reports; legislative developments; enforcement actions; news reports; Web site evaluations; recommended and nonrecommended books; and other information relevant to consumer protection and consumer decision-making. Its primary focus is on health, but occasionally it includes non-health scams and practical tips.

Prohibited drug found in dietary supplements. Piracetam has been touted as a brain-enhancing substance despite poor evidence of its efficacy. Although it is not approved as a drug and is prohibited as a dietary supplement ingredient in the United States, U. S.-based researchers were able to purchase two samples of each of 12 brands of piracetam products online from sellers they identified through a Google search. [Cohen P and others. Presence of piracetam in cognitive enhancement dietary supplements. JAMA Internal Medicine. doi:, Nov 25, 2019] Five of those brands were labeled as dietary supplements. Chemical analysis revealed that the piracetam content ranged from 85% to 188% of the labeled dosage. The researchers noted that (a) known adverse effects of piracetam include anxiety, insomnia, agitation, depression, drowsiness, and weight gain, and (b) the effects of the doses found, particularly in elderly consumers with poor kidney function are unknown. They concluded:

Our findings demonstrate that even after the FDA rejected an application to market piracetam as a new supplement ingredient, the drug was nevertheless introduced into the marketplace. Despite FDA warning letters, the products remain on the market. Until the law governing supplements is reformed such that products adulterated with drugs can be effectively removed from the market, clinicians should advise patients that supplements marketed as cognitive enhancers may contain prohibited drugs at supratherapeutic doses.

Complications attributed to intravenous colloidal silver. A report has been published about three people whose condition worsened after receiving multiple intravenous infusiions at a "wellness center" for alleged Lyme disease. Each was eventually seen by a hematologist and found to have copper-deficiency-induced anemia with abnormal blood cell counts. One patient was then treated successfully with supplemental copper apheresis and an antidepressant. The other two patients refused apheresis and follow-up with the hematologist. After the authors of this case series complained to the Texas Medical Board, the initial treating physician agreed to voluntarily surrender his medical license. [Natelson EA and others. Anemia and leukopenia following intravenous colloidal silver infusions—clinical and hematological features, unique peripheral blood film appearance and effective therapy with supplemental oral copper and apheresis. Clinical Case Reports 7:157-1762, 2019] The authors concluded:

As this report illustrates, the use of infused colloidal silver as a primary or adjunctive therapy to treat alleged Lyme disease or other systemic infections must be condemned as both ineffective and with predictable long‐term toxicity. Silver administered by the intravenous route is more toxic than that associated with oral preparations because of both higher dose and the apparent inability of the body to excrete this material, resulting in continuous prolonged and profound intravascular colloidal silver exposure.

Quackwatch has additional information about colloidal silver's risks and lack of therapeutic value.

More stem cell product distributors warned. The U.S. Food and Drug Administration (FDA) has expressed concerns to three more stem cell marketers:

The FDA has also issued a safety alert about clinics across the U.S., including some that market unapproved stem cell treatments or unapproved products said to contain exosomes—a type of particle released from cells in the body. FDA's safety alert warns about multiple recent reports of serious adverse events experienced by patients in Nebraska who were treated with such products. [FDA sends warning to companies for offering unapproved umbilical cord blood products that may put patients at risk. FDA news release, Dec 6, 2019]

Synovia marketers settle FTC charges. Colorado-based A.S. Research, LLC (ASR) and its owners, Stephen J. Young and Michael K. Ledeboer, have agreed to a proposed Federal Trade Commission (FTC) settlement order that:

According to the FTC's complaint, defendants:

[FTC stops marketers from making false arthritis treatment claims. FTC press release. Dec 5, 2019]

Previous Issue || Next Issue

This page was posted on September 9, 2019.